The European Commission has approved the use of Biofrontera’s topical prescription drug, Ameluz, in combination with daylight Photodynamic Therapy (daylight PDT). The approval for daylight PDT is expected to greatly increase the market potential for Ameluz in Europe, and to improve the drug’s reimbursement status in Germany. The approval by the European Commission followed a…